Amylyx reports promising GLP-1 blocker results while Summit faces survival setbacks and Definium shows anxiety therapy benefit

Amylyx said its investigational GLP-1 blocker avexitide cut the combined rate of level 2 and level 3 hypoglycemic events by about 55% in patients with post‑bariatric hypoglycemia, beating analyst expectations and marking a turnaround after the company withdrew its ALS drug two years ago.

Definium announced positive early data for an LSD‑based therapy aimed at treating anxiety, indicating a potential new approach in the mental‑health space.

Summit Therapeutics, in partnership with Akeso, received Chinese regulatory approval for its VEGF/PD‑1 bispecific antibody ivonescimab in squamous non‑small cell lung cancer, but the accompanying label showed a diminishing progression‑free survival benefit, raising questions about its U.S. market prospects.

Neurocrine reported serious adverse events in patients treated with its drug for Prader‑Willi syndrome, highlighting safety concerns for the therapy.

Eli Lilly announced efforts to curb the black‑market sale of its next‑generation obesity candidate retatrutide, aiming to protect the drug’s integrity and patient safety.